We are live on ! Find out more
AUPH icon

Aurinia Pharmaceuticals
AUPH

68 hedge funds and large institutions have $108M invested in Aurinia Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 14

13% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 15

10% more funds holding

Funds holding: 62 → 68 (+6)

0.32% more ownership

Funds ownership: 28.06% → 28.38% (+0.32%)

27% less capital invested

Capital invested by funds: $147M → $108M (-$39M)

71% less call options, than puts

Call options by funds: $865K | Put options by funds: $2.99M

Holders
68
Holders Change
+6
Holders Change %
+9.68%
% of All Funds
1.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
17
Reduced
15
Closed
14
Calls
$865K
Puts
$2.99M
Net Calls
-$2.12M
Net Calls Change
+$1.29M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$4M
2
PC
Polar Capital
United Kingdom
+$3.78M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.98M
4
Franklin Resources
Franklin Resources
California
+$2.3M
5
Goldman Sachs
Goldman Sachs
New York
+$1.77M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.74M
2
CLCM
Crawford Lake Capital Management
New Jersey
-$2.86M
3
RG
Redmile Group
California
-$2.08M
4
SC
Sculptor Capital
New York
-$1.16M
5
Morgan Stanley
Morgan Stanley
New York
-$1.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
51
Bank of America
North Carolina
$42K +$50K +9,000 +9,000%
Canada Life
52
Canada Life
Manitoba, Canada
$31K +$37.4K +6,730 New
BBHC
53
Brown Brothers Harriman & Co
New York
$29K – – –
TRCT
54
Tower Research Capital (TRC)
New York
$25K +$10.3K +1,859 +74%
Citigroup
55
Citigroup
New York
$23K +$10.2K +1,835 +61%
PA
56
Parallel Advisors
California
$23K +$16.7K +3,000 +150%
SAM
57
Shell Asset Management
Netherlands
$19K +$22.8K +4,100 New
FDCDDQ
58
Federation des caisses Desjardins du Quebec
Quebec, Canada
$17.7K +$21.1K +3,800 +4,270%
CSS
59
Cubist Systematic Strategies
Connecticut
$16K +$19.3K +3,472 New
Simplex Trading
60
Simplex Trading
Illinois
$13K +$17.1K +3,073 New
CG
61
Cutler Group
California
$11K -$15.5K -2,800 -53%
CA
62
Calton & Associates
Florida
$11K +$11.1K +2,000 New
FANJ
63
Financial Architects (New Jersey)
New Jersey
$9K -$4.44K -800 -29%
Fifth Third Bancorp
64
Fifth Third Bancorp
Ohio
$9K – – –
TCOV
65
Trust Company of Vermont
Vermont
$5K – – –
LTFS
66
Ladenburg Thalmann Financial Services
Florida
$3K – – –
HR
67
Howe & Rusling
New York
$2K – – –
TDC
68
Thompson Davis & Co
Virginia
$1K – – –
CLCM
69
Crawford Lake Capital Management
New Jersey
– -$2.86M -455,656 Closed
RG
70
Redmile Group
California
– -$2.08M -332,310 Closed
SC
71
Sculptor Capital
New York
– -$1.16M -185,100 Closed
AA
72
ALPS Advisors
Colorado
– -$515K -82,163 Closed
ICOA
73
Investment Centers of America
North Dakota
– -$376K -60,000 Closed
Parallax Volatility Advisers
74
Parallax Volatility Advisers
California
– -$312K -49,702 Closed
VF
75
Virtu Financial
New York
– -$232K -37,009 Closed
1 2
3
4

AUPH Hedge Fund Activity: Q4 2017 in Review

68 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2017, worth a combined $108M — down 27% from $147M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new AUPH positions and 14 closed out — a net gain of 6 holders — while 17 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $4M. The largest seller was Fidelity Investments, cutting an estimated $5.74M.

  • 68 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2017, up from 62 in Q3 2017.
  • Funds reported $108M of Aurinia Pharmaceuticals stock for Q4 2017, down 27% quarter-over-quarter.
  • 20 funds opened new Aurinia Pharmaceuticals positions in Q4 2017 and 14 closed out, a net change of +6 holders.
  • The largest Aurinia Pharmaceuticals buyer in Q4 2017 was BlackRock, an estimated $4M added.
  • The largest Aurinia Pharmaceuticals seller in Q4 2017 was Fidelity Investments, an estimated $5.74M sold.

Based on aggregated 13F filings for Q4 2017.